ReShape Lifesciences Inc. (OTCMKTS:RSLSD) major shareholder Armistice Capital Master Fund purchased 400,636 shares of the stock in a transaction on Tuesday, November 12th. The stock was acquired at an average price of $5.25 per share, with a total value of $2,103,339.00. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Armistice Capital Master Fund also recently made the following trade(s):
- On Monday, November 18th, Armistice Capital Master Fund purchased 3,735 shares of ReShape Lifesciences stock. The stock was acquired at an average price of $5.25 per share, with a total value of $19,608.75.
RSLSD opened at $6.97 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.07 and a current ratio of 1.17. ReShape Lifesciences Inc. has a 12 month low of $2.91 and a 12 month high of $306.00.
ReShape Lifesciences Company Profile
ReShape Lifesciences Inc, a medical device company, focuses on the design, development, and commercialization of technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy; and Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy.
Further Reading: Understanding the two types of arbitrage
Receive News & Ratings for ReShape Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReShape Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.